Abdul Mannan: Why AML inv(16) Isn’t Just “Favourable”
Dr Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, posted on LinkedIn:
“The ‘Harlequin’ Leukemia: Why AML inv(16) Isn’t Just ‘Favourable’
AML with inv(16)(p13.1q22) is one of the most visually striking and biologically distinct subtypes we see. Textbooks call it ‘favourable.’ Clinicians know it’s more complicated.
1. Morphology: The Harlequin Clue
- The FAB M4Eo marrow gives it away.
- Those eosinophils with mixed orange and purple granules are almost diagnostic.
- And if the blasts show CD2 positivity, you already know what the karyotype is likely to say.
2. The Engine: CBFB::MYH11
- The fusion traps RUNX1 in the cytoplasm, freezing maturation and driving the disease. Classic CBF biology.
3. The ELN 2022 Twist: KIT Isn’t a Deal-Breaker
- About one-third carry KIT mutations, especially D816V.
- Yes, relapse risk climbs.
- But ELN 2022 keeps CBF-AML in the favourable group regardless because overall survival remains excellent.
Practical point:
- Not a transplant trigger in CR1, but absolutely a reason for closer molecular surveillance.
4. Treatment: Do It Properly or Don’t Call It Favourable
- Induction:
- CD33-high disease → add Gemtuzumab Ozogamicin where possible.
- Consolidation:
- No shortcuts.
- This subtype demands high-dose Cytarabine (HiDAC). Standard-dose consolidation is simply not enough.
5. MRD: Your Early Warning System
- Monitor the CBFB::MYH11 transcript every 3 months for two years.
- A rising log value means molecular relapse long before counts crash.
Bottom Line
- inv(16) isn’t “easy AML.”
- It’s highly curable only when treated with precision: recognise the morphology, respect the molecular modifiers, use GO in induction, and commit to HiDAC consolidation.
How are you using Gemtuzumab in your CBF-AML pathways? And what’s your approach to KIT-mutated cases in CR1? Happy to hear how others are tackling this.”
Follow the latest with Hemostasis Today.
-
Jul 21, 2026, 21:12Ammar Al Awawdeh: Bridging the Hemostatic Gap – Functional Platelet Salvage in CPB
-
Jul 21, 2026, 19:44Shinya Goto: JCS/JPCPHS 2025 Guideline Now Available in English
-
Jul 21, 2026, 19:43Abdul Mannan: Why Is HbS or HbD Approximately 40% in Heterozygotes Rather Than 50%?
-
Jul 21, 2026, 19:42Haemophilia Maintains a 2025 Impact Factor of 3.0 – WFH
-
Jul 21, 2026, 19:41Wolfgang Miesbach: SR604 Restores Thrombin Generation Where It Is Needed
-
Jul 21, 2026, 19:40Filmon Tesfay: Our New Case Report on Cerebral Venous Thrombosis Is Now Published
-
Jul 21, 2026, 15:02Sham Zamil: The Role of ABO Compatibility in Platelet Pooling
-
Jul 21, 2026, 13:43Dima Shulkin: Assessing AI-Driven Blood Test Screening for Colorectal Cancer
-
Jul 21, 2026, 13:24Benoit Mores: National Initiative Targets Better Cardiovascular Outcomes